Literature DB >> 16891398

Galectin-1 in secondary alveolar septae of neonatal mouse lung.

Jennifer J Foster1, Kelli L Goss, Caroline L S George, Peter J Bangsund, Jeanne M Snyder.   

Abstract

In mice, alveolarization occurs during postnatal days 4 through 12, when secondary alveolar septae create thin-walled alveoli in the distal lung. We hypothesized that genes predominantly expressed in newly forming secondary alveolar septae influence the process of alveolarization. To address this hypothesis, tips of secondary alveolar septae were isolated from sections of postnatal day 6 mouse lung tissue using laser capture microdissection. Total RNA was isolated and amplified from the dissected alveolar septal tips and from intact postnatal day 6 lung tissue. Gene expression in the samples was characterized using Affymetrix mouse U74AN2 GeneChips. Galectin-1 was an abundantly expressed transcript that was enriched in the alveolar septal tips compared with levels in the whole lung tissue. Galectins are beta-galactoside-binding proteins involved in the regulation of cell proliferation, differentiation, and apoptosis in fibroblasts, muscle cells and endothelial cells, cell types that are present in the alveolar wall. Immunostaining in postnatal day 6 lung tissue confirmed that galectin-1 protein is concentrated in the tips of secondary alveolar septae, predominantly in myofibroblasts. Fibroblasts isolated from day 6 neonatal mouse lung tissue contained galectin-1 protein. Real-time PCR demonstrated that galectin-1 mRNA levels in mouse lung tissue peak at postnatal day 6. Immunoblot analysis confirmed that peak levels of lung galectin-1 protein are found at postnatal days 6 to 12. The increased expression of galectin-1 at the site and time of ongoing alveolarization in the newborn mouse is suggestive that galectin-1 may play an important role in this critical aspect of lung development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16891398     DOI: 10.1152/ajplung.00054.2006

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  8 in total

1.  Expression profiles of the mouse lung identify a molecular signature of time-to-birth.

Authors:  Alvin T Kho; Soumyaroop Bhattacharya; Brigham H Mecham; Jungha Hong; Isaac S Kohane; Thomas J Mariani
Journal:  Am J Respir Cell Mol Biol       Date:  2008-07-29       Impact factor: 6.914

2.  Prevention of trauma/hemorrhagic shock-induced lung apoptosis by IL-6-mediated activation of Stat3.

Authors:  Ana Moran; Anna I Tsimelzon; Mary-Ann A Mastrangelo; Yong Wu; Bi Yu; Susan G Hilsenbeck; Valeria Poli; David J Tweardy
Journal:  Clin Transl Sci       Date:  2009-02       Impact factor: 4.689

3.  Galectins in hematological malignancies.

Authors:  Yves St-Pierre
Journal:  Am J Blood Res       Date:  2011-09-07

Review 4.  Aberrant signaling pathways of the lung mesenchyme and their contributions to the pathogenesis of bronchopulmonary dysplasia.

Authors:  Shawn K Ahlfeld; Simon J Conway
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2011-11-28

5.  Periostin downregulation is an early marker of inhibited neonatal murine lung alveolar septation.

Authors:  Shawn K Ahlfeld; Yong Gao; Jian Wang; Emrin Horgusluoglu; Esther Bolanis; D Wade Clapp; Simon J Conway
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2013-05-30

6.  Lung interstitial cells during alveolarization.

Authors:  Chang Won Choi
Journal:  Korean J Pediatr       Date:  2010-12-31

7.  Haploinsufficiency of Col5a1 causes intrinsic lung and respiratory changes in a mouse model of classical Ehlers-Danlos syndrome.

Authors:  Jordan Fett; Milena Dimori; John L Carroll; Roy Morello
Journal:  Physiol Rep       Date:  2022-04

8.  Gene Expression Signatures Point to a Male Sex-Specific Lung Mesenchymal Cell PDGF Receptor Signaling Defect in Infants Developing Bronchopulmonary Dysplasia.

Authors:  Christina T Fulton; Tracy X Cui; Adam M Goldsmith; Jennifer Bermick; Antonia P Popova
Journal:  Sci Rep       Date:  2018-11-20       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.